Sacituzumab Govitecan for ER+/HER2 Low/Ultra Low Metastatic Breast Cancer
This study is looking at how well the medication sacituzumab govitecan (SG) works in people with metastatic (cancer that has spread), hormone receptor-positive (HR+), and HER2 low/ultra low breast cancer. Specifically, it's for those who have already been treated with another drug called trastuzumab deruxtecan (T-DXd). Sacituzumab govitecan is given through an IV infusion on specific days of a 21-day cycle. The main goal is to see how many participants respond to the treatment over 24 months. You may be able to join if you are 18 or older and have metastatic or advanced breast cancer that is HER2 low/ultra low.
- Study design
- This is an interventional study planning to enroll 75 participants. It is not specified if it is randomized or blinded.
- What's involved
- You would receive sacituzumab govitecan as an IV infusion on Days 1 and 8 of continuous 21-day cycles. The first infusion takes about 3 hours, and later ones take 1-2 hours if well tolerated.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will measure your response to treatment for 24 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT06263543
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
Recruiting
PHASE2Ages 18+InterventionalTreatmentReshma L. Mahtani, D.O.Investigator-initiated
~75 participants
Updated 2026-08-12 on ClinicalTrials.gov
What's tested:Sacituzumab govitecan
At a glance
Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Overall response rate (ORR)
Measured over 24 months
Conditions
Where it's being run
3 sites across 3 statesFlorida1
Georgia1
Kansas1
Study leadership
- Reshma L Mahtani, D.O. · PRINCIPAL_INVESTIGATOR · Baptist Health Herbert Wertheim Cancer Institute
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Provision of signed and dated informed consent form.
Stated willingness to comply with all study procedures and availability for the duration of the study.
Individuals ≥ 18 years of age.
4\. Histologically confirmed metastatic or advanced and unresectable breast cancer that is HER2 LOW/ULTRA LOW by local testing on either the primary or any metastatic site. HER2 LOW is defined as: (IHC 2+/ISH- or IHC 1+ (ISH- or untested)) and HER2 ULTRA LOW is defined as: IHC0+ (faint membrane staining up to 10%)
Histologically confirmed metastatic or advanced and unresectable breast cancer that is hormone receptor positive (estrogen receptor and/or progesterone receptor positive) defined as \>1% on any metastatic site or the primary tumor.
Endocrine-refractory (as per investigator judgement) and may have received any number of prior endocrine therapies (alone or in combination with cyclin-dependent kinase (CDK)4/6 inhibitor, everolimus, alpelisib, acapivasertib or inavolisib).
Received a CDK4/6 inhibitor either alone or in combination with endocrine therapy (in the adjuvant or metastatic setting) with any duration of therapy permitted.
Received at least 1 but no more than 4 prior systemic chemotherapy regimens in the metastatic setting. Prior ADCs count as a line of systemic chemotherapy. Prior PARP inhibitor use counts as a line of systemic therapy.
Prior treatment with T-DXd (discontinued for progression and/or intolerance), which does not have to be the treatment immediately prior to enrollment on trial.
Documented clinical and/or radiographic disease progression after most recent therapy, unless immediate prior therapy was T-DXd which was discontinued for toxicity.
Measurable disease, as per RECIST V1.1 - a. If a patient has bone-only disease, they are eligible as long as there is a lytic lesion that is considered measurable. Blastic-only bone lesions are not allowed.
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2.
Adequate organ and bone marrow function within 28 days before enrollment. For all parameters listed below, the most recent results available must be used:
Adequate treatment washout period before randomization, defined as:
Evidence of post-menopausal status or for individuals of childbearing potential must have a negative serum beta-human chorionic gonadotropin (ß-hCG) at screening or baseline. Individuals of childbearing potential are defined as those who are not surgically sterile (i.e., underwent bilateral tubal occlusion, bilateral salpingectomy, bilateral oophorectomy, or complete hysterectomy) or post-menopausal.
Individuals of childbearing potential who are sexually active with a non-sterilized male partner must agree to use at least one highly effective method of contraception from the time of registration through final study treatment. Not all methods of contraception are highly effective.
Non-sterilized male patients who are sexually active with a partner of childbearing potential must agree to use a condom with spermicide from registration and throughout duration of the study treatment.
Abstinence (not having sexual relations with a person who can get you pregnant)
Non-hormonal Intrauterine Device (IUD)
Vasectomy
Sterilization
Bilateral tubal occlusion
Exclusion
Locally advanced MBC (stage IIIc) in individuals who are candidates for curative intent therapy at the time of study enrollment.
Patients with brain metastases (BM) except for asymptomatic treated BM not requiring ongoing corticosteroid treatment with stable lesions on baseline/screening brain MRI. Patients who require treatment of brain metastases are eligible after 14 days post receipt of surgery or radiation, if felt to be clinically stable and not requiring ongoing corticosteroid treatment.
Active serious infection requiring ongoing antibiotics.
History of an anaphylactic reaction to irinotecan.
Pregnant or breastfeeding.
Ongoing treatment with another investigational drug or other interventional trial.
Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.
Any other condition that may put a participant at higher risk, at the discretion of the investigator.
What this trial measures
- Overall response rate (ORR)24 months
ORR will be assessed using Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1). ORR is defined as the percentage of participants who received at least one dose of SG and have achieved a complete response (CR) or partial response (PR) as assessed by the local investigator.